



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 30 May 2022 (#21)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notices

Financial Conflict of Interest: All Principal Investigators (PIs) and Key Personnel (KP) of **all current NIH grants**, direct and subawards, **MUST complete** the NIH training and submit the certificate the Grants Management Office. For all new applications, all PI's & KP must complete the certificate before the application can be submitted to NIH. This is in addition to the FCOI declarations that must be signed.

- FMHS contact: cdevries@sun.ac.za
- Stellenbosch Campus contact lizelk@sun.ac.za.

Link to the training: https://grants.nih.gov/grants/policy/coi/tutorial2018/story_html5.html

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Notices of Special Interest

[NOT-HL-22-024](#) **Diagnostics and Disease Management Tools for Use in Underserved**. The purpose of this NOSI is to stimulate research focused on the development of transformative diagnostics and disease management tools for heart, lung, blood, or sleep (HLBS) disorders that are designed to meet the needs of the underserved populations. Underserved populations, for the purpose of this NOSI, can include racial and ethnic minorities, immigrants, the homeless, low-income individuals, the uninsured and people who live in communities that are socioeconomically disadvantaged, rural or have few health care resources. Please see [NOT-OD-20-031](#) for NIH definitions. Special consideration will be given to technology solutions that are accessible and feasible in these communities. Working with community partners is required throughout the project to ensure successful development and implementation. Due dates up to 6 July 2025. Use the following FOA: [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed).

[NOT-OD-22-123](#) NIH Research Project Grants on Down Syndrome (R01) for the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromeE) Project. Within the past 25 years, the average lifespan for a person with Down syndrome has doubled, from 30 to 60 years. Despite this increase in lifespan, individuals with Down syndrome and their families face significant and changing health challenges with age, and they have often been excluded from participation in research that could improve their health outcomes and quality of life. The purpose of this NOSI is to support research project grant (R01) applications that are focused on Down syndrome and that meet programmatic objectives for the INCLUDE Project. Sharing of resources and effective communication of outputs of appropriate interest to broader communities are a high priority of the [INCLUDE Project](#). Applicants responding to this NOSI are strongly encouraged to describe plans for rapid sharing of data and results as well as innovative data analytics approaches. This notice applies to due dates on or after 5 July 2022 and subsequent receipt dates through 1 May 2025. Submit applications for this initiative using one of the following FOA's:

[PA-20-183](#) - Research Project Grant (Parent R01 Clinical Trial Required)

[PA-20-184](#) - NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)

[PA-20-185](#) - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

[NOT-OD-22-124](#) Mentored Career Development Awards to Foster the Careers of Investigators Pursuing Research Related to Down syndrome as Part of the INCLUDE Project. The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndrome (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome (DS). This Notice of Special Interest (NOSI) announces NIH support for the professional development of early career scientists aiming to establish a career in DS-related research. By providing these scientists with training, resources, and mentorship, the NIH intends to support the career development of junior investigators in DS who will lead future research to improve the understanding of the biology of DS and support development of new treatments for health conditions experienced by those with DS. This notice applies to due dates through to 13 November 2024. Submit applications for this initiative using one of the following FOA's:

[PAR-21-251](#) Emerging Global Leader Award (K43 Independent Clinical Trial Required)

[PAR-21-252](#) Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)

Funding Opportunity Announcements (FOA)

1. Resources Access for Preclinical Integrated Drug Development (RAPIDD) Program (X01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-22-185](#)

Type: X01

Application Due Date: 1 September 2022 through to 17 January 2025. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement. The purpose of this FOA is to provide investigators working on the development of novel therapeutic products for HIV and HIV-associated co-infections (hepatitis B virus, hepatitis C virus, and Mycobacterium tuberculosis) with a mechanism to request NIAID DAIDS preclinical services to fill gaps in their product development efforts and facilitate the advancement of promising therapeutics from bench to clinics.

Budget: Not Applicable. There are no funds awarded via the X01 Resource Access Award. The scope of the proposed project should determine the project period. The maximum project period for Topics A, C, and D is one (1) year, while the maximum project period for Topic B is two (2) years.

2. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Program Project Grants for HIV Research (P01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-HD-23-026](#)

Type: P01

Application Due Date: 10 August 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement. This Funding Opportunity Announcement (FOA) invites submission of Program Project (P01) applications to support integrated, multi-project research programs that address HIV scientific areas relevant to the NICHD mission as a well-defined, central research focus or objective.

Budget: NICHD/NIH intends to commit \$3 Million in FY 2023 to fund up to 2 awards. Application budgets are limited to 1M/year in direct costs and should reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

3. Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa): Research Education Program (UE5 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-RM-22-022](#)

Type: UE5

Application Due Date: 28 September 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement. The NIH Research Education Program (UE5) supports research education activities in the mission areas of the NIH. The overarching goal of this UE5 program is to support educational activities that complement and/or enhance the training of a workforce to meet the biomedical, behavioral and clinical research needs of the Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa) program. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development. The goal of DS-I Africa is to spur new health discoveries and catalyze innovation in healthcare, public health, and health research on the continent through application of data science. Applications are encouraged that propose innovative, state-of-the-art, hands-on programs that advance the goal of DS-I Africa. The courses should focus on activities that target educational needs or gaps in the DS-I Africa consortium, and thus applicants must have support from current [DS-I Africa awardees](#). Applications must be submitted from African academic or other non-profit organizations

Budget: NIH Common Fund intends to commit up to \$3,000,000 over 3 years to fund five awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. Applications are limited to \$200,000 total costs per year. The maximum project period is 3 years.

4. Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa): Partnership for Innovation Research Projects (U01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-RM-22-023](#)

Type: U01

Application Due Date: 28 September 2022. AIDS date: 6 December 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement. This Funding Opportunity Announcement (FOA) seeks applications for Partnership for Innovation Research Projects as part of a broader ongoing initiative entitled Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa). The goal of DS-I Africa is to spur new health discoveries and catalyze innovation in healthcare, public health, and health research on the continent through application of data science. DS-I Africa Partnership for Innovation Research Projects are meant to support discrete research projects led by investigators in Africa to expand the DS-I Africa consortium. Applicants will propose innovative health data science research and solutions in Africa with the ability to advance population-relevant, affordable, acceptable, and scalable data science solutions and, in the long-term, demonstrate the ability of these solutions to improve health in Africa. Applications should propose partnership with a non-academic partner that enhances the potential impact of the research. Since one goal of this FOA is to expand the DS-I Africa consortium, either the applicant organization or proposed partner should not be a current member of the consortium. Additionally, these projects are aimed to enhance the career pipeline and retention of health data scientists in Africa by supporting a minimum number of new and early-stage investigators. Applications must be submitted from African academic or other non-profit organizations. Proposed partnerships with organizations outside the applicant institution can include all types of organizations in Africa, the U.S., or other countries.

Budget: The NIH Common Fund intends to commit \$8,200,000 over three years to fund up to 12 awards. It is anticipated that half of funded projects will be awarded to new and early-stage investigators. The requested budget needs to reflect the actual needs of the proposed project. DS-I Africa Partnership for Innovation Research Project applications are limited to \$250,000 per year in total costs. The scope of the proposed DS-I Africa Partnership for Innovation Research Project should determine the project period. The maximum project period is 3 years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Division for Research Development (DRD)
Stellenbosch Campus
2041 Krotoa Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105